ES2179729B1 - Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. - Google Patents
Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.Info
- Publication number
- ES2179729B1 ES2179729B1 ES200000710A ES200000710A ES2179729B1 ES 2179729 B1 ES2179729 B1 ES 2179729B1 ES 200000710 A ES200000710 A ES 200000710A ES 200000710 A ES200000710 A ES 200000710A ES 2179729 B1 ES2179729 B1 ES 2179729B1
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical form
- obtaining
- water
- presentation
- isoniazid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960003350 isoniazid Drugs 0.000 title abstract 4
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 title abstract 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 title abstract 4
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000007787 solid Substances 0.000 title abstract 3
- XLYOFNOQVPJJNP-PWCQTSIFSA-N Tritiated water Chemical compound [3H]O[3H] XLYOFNOQVPJJNP-PWCQTSIFSA-N 0.000 title 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 abstract 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 abstract 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 abstract 3
- 229960001225 rifampicin Drugs 0.000 abstract 3
- 239000008187 granular material Substances 0.000 abstract 2
- 238000002156 mixing Methods 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 238000000265 homogenisation Methods 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 229940049413 rifampicin and isoniazid Drugs 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Forma farmacéutica sólida de administración oral dispersable en agua que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtención y forma de presentación de dicha forma farmacéutica. La forma farmacéutica contiene rifampicina, isoniazida y piridoxina hidrocloruro como principios activos, en una matriz sólida granular dispersable en agua, que puede ser reconstituida en agua, dando lugar a una suspensión de sabor agradable. El procedimiento de obtención de dicha forma farmacéutica comprende la mezcla simple de los componentes o bien la obtención, por separado, de unos granulados de rifampicina y de isoniazida, y la mezcla y homogeneización de dichos granulados. La forma farmacéutica es adecuada para la elaboración de una forma de presentación de un medicamento que contiene rifampicina, isoniazida y piridoxina hidrocloruro, por ejemplo, en forma de sobres monodosis que contienen dicha forma farmacéutica en una dosificación terapéuticamente.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200000710A ES2179729B1 (es) | 2000-03-23 | 2000-03-23 | Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. |
| PCT/ES2001/000089 WO2001070172A2 (es) | 2000-03-23 | 2001-03-08 | Forma farmaceutica solida de administracion oral dispersable en agua que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200000710A ES2179729B1 (es) | 2000-03-23 | 2000-03-23 | Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2179729A1 ES2179729A1 (es) | 2003-01-16 |
| ES2179729B1 true ES2179729B1 (es) | 2003-12-16 |
Family
ID=8492832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200000710A Expired - Fee Related ES2179729B1 (es) | 2000-03-23 | 2000-03-23 | Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. |
Country Status (2)
| Country | Link |
|---|---|
| ES (1) | ES2179729B1 (es) |
| WO (1) | WO2001070172A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL149030A0 (en) * | 2000-08-09 | 2002-11-10 | Panacea Biotec Ltd | Pharmaceutical compositions containing rifampicin, isoniazid or combinations thereof |
| WO2004082586A2 (en) * | 2003-03-17 | 2004-09-30 | Affinium Pharmaceuticals, Inc. | Phamaceutical compositions comprising inhibitors of fab i and further antibiotics |
| EP2687533B1 (en) | 2006-07-20 | 2017-07-19 | Debiopharm International SA | Acrylamide derivatives as FAB I inhibitors |
| US8263613B2 (en) | 2007-02-16 | 2012-09-11 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab I inhibitors |
| SMT201900411T1 (it) | 2012-06-19 | 2019-09-09 | Debiopharm Int Sa | Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide |
| CN103816545A (zh) * | 2013-10-30 | 2014-05-28 | 安徽万邦医药科技有限公司 | 含有利福平和十二烷基硫酸钠的药物组合物 |
| BR122023021456A2 (pt) | 2016-02-26 | 2024-02-20 | Debiopharm International S.A. | Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica |
| FI3923914T3 (fi) | 2019-02-14 | 2023-04-27 | Debiopharm Int Sa | Afabisiiniformulaatio, menetelmä sen valmistamiseksi |
| MA56184A (fr) | 2019-06-14 | 2022-04-20 | Debiopharm Int Sa | Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1755780A1 (ru) * | 1989-10-30 | 1992-08-23 | Киевский государственный институт усовершенствования врачей | "Сухой безалкогольный напиток "Стимул" |
| PL192959B1 (pl) * | 1996-08-14 | 2006-12-29 | Astellas Pharma Europ Bv | Kompozycja zawierająca granulat składający się z rozpuszczalnego w wodzie związku i substancji celulozowej |
| IT1289883B1 (it) * | 1996-10-09 | 1998-10-19 | Lupin Lab Ltd | Composizione farmaceutica antitubercolare e procedimento per la sua produzione |
-
2000
- 2000-03-23 ES ES200000710A patent/ES2179729B1/es not_active Expired - Fee Related
-
2001
- 2001-03-08 WO PCT/ES2001/000089 patent/WO2001070172A2/es not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001070172A2 (es) | 2001-09-27 |
| ES2179729A1 (es) | 2003-01-16 |
| WO2001070172A3 (es) | 2002-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO993520D0 (no) | Doseringsformer og fremgangsmåte for å bedre erektil dysfunksjon | |
| ECSP045102A (es) | Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo | |
| BRPI0403935B8 (pt) | formas de dosagem de azitromicina com efeitos colaterais reduzidos | |
| NO20025621D0 (no) | Farmasöytisk sammensetning med vedvarende frigjöring for parenteral administrasjon av hydrofile forbindelser | |
| TW200505498A (en) | Sugar-free oral transmucosal solid dosage forms and uses thereof | |
| DK1246622T3 (da) | Nye substituerede benzimidazol dosisformer og metoder til deres anvendelse | |
| PT833618E (pt) | Forma farmaceutica solida para utilizacao oral | |
| SE0102276D0 (sv) | Device and method for the administration of a medicament | |
| WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
| ECSP045409A (es) | Composiciones y metodos para dosificar liposomas de ciertos tamaños a fin de tratar o prevenir enfermedades. | |
| WO2005055921A3 (en) | Compositions for treatment of ear disorders and methods of use thereof | |
| EP1365749A4 (en) | PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS | |
| NO306894B1 (no) | Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet | |
| MX2007015480A (es) | Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada. | |
| NO20031409D0 (no) | Ionestyrkeuavhengig farmasöytiske preparat med langvarig frigivelse | |
| AP2003002763A0 (en) | Controlled release formulations for oral administration | |
| ATE262893T1 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| ES2184561B1 (es) | Forma farmaceutica solida de administracion oral dispersable en agua para el tratamiento de la tuberculosis conteniendo rifampicina, isoniazida, pirazinamida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. | |
| ES2179729A1 (es) | Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica. | |
| WO2003045305A3 (en) | Acetaminophen compositions | |
| ATE462419T1 (de) | Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren | |
| AP2218A (en) | Azithromycin dosage forms with reduced side effects | |
| WO2002056867A3 (en) | Extended release pharmaceutical compositions containing beta-lactam antibiotics | |
| WO2003105811A8 (en) | PROGRESSIVE RELEASE COMPOSITIONS AND METHOD OF USE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20030116 Kind code of ref document: A1 |
|
| PC2A | Transfer of patent | ||
| FG2A | Definitive protection |
Ref document number: 2179729B1 Country of ref document: ES |
|
| PC2A | Transfer of patent |
Free format text: CHIESI ESPANA, S.A. |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20200630 |